Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04748042 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion pushed from May 2026 to May 2027
    • Primary completion date changed from estimate of May 2026 to May 2, 2026
    v8
  2. Primary and study completion dates: Dec 2025 to May 2026v7
  3. Primary and study completion dates: May 2025 to Dec 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 29 to confirmed 21
    • Site details revised
    v6
  4. 3 versions Re-verified since Sep 21, 2022, no change to tracked fieldsv3-v5
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Apr 2025 to May 2025
    • Study completion date: Oct 2025 to May 2025
    • Start date changed from estimate of Apr 2021 to May 28, 2021
    • Site details revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prostate cancer. This is a phase 2 study to deliver focal radiation with pulsed systemic therapy of Abiraterone, ADT and Lynparza (olaparib) in men with castration sensitive oligometastatic prostate cancer.
Trial Details
NCT Number NCT04748042
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions
(from sponsor)		 Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
Related terms Prostatic Neoplasms
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov